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The human ovarian carcinoma cell line, IGROVl, produces two forms of folate binding protein (FBP), the membrane form that is anchored to 
the cell surface by a glycosylphosphatidylinositol ail and the soluble form that is shed into the tissue culture medium. Both forms are recognized 
by the monoclonal antibodies MOvl8 and MOvl9. Here we describe their purification and biochemical characterization. The purified soluble 
protein appeared as a single band with an apparent h4, of 36 kDa after SDS-PAGE, whereas the membrane form appeared as a single band with 
an apparent M, of 38 kDa. The size difference between the two forms of FBP was confirmed by gel filtration of both the native and the 
N-glycanase-treated proteins. Both purified proteins had equal capacity to bind folic acid. The immunological cross-reactivity and the folic acid 
binding capability of the FBPs extracted from IGROVl gave more evidence of the possible existence of a precursor-product relationship between 
them. 
Folate binding protein; Ovarian carcinoma: Glycosylphosphatidylinositol linkage 
1. INTRODUCTION 
The monoclonal antibodies MOvl8 and MOv19 rec- 
ognize a glycoprotein molecule with a M, of kDa that 
is over-expressed in ovarian carcinoma cells [l]. This 
membrane glycoprotein expressed by the IGROVl 
ovarian carcinoma cell line can be released from the cell 
surface by treatment with PI-PLC, confirming the pres- 
ence of a GPI linkage [2]. The cDNA corresponding to 
the GPI-linked protein was recently cloned by Coney et 
al. [3] from an IGROVl cDNA library and by Campbell 
et al. [4] using cDNA libraries established from SKOv3 
ovarian carcinoma and HT29 colon carcinoma cells 
confirming its identity as human FBP. A GPI-linked 
form was also reported to exist in the membrane of the 
KB epidermal carcinoma cell line [5] and human pla- 
centa [6]. A soluble form of FBP has also been found 
in the growth medium of KB [7]. Pulse-chase experi- 
ments have indicated a probable precursor-product re- 
lationship between the membrane-bound and soluble 
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2.4. Purification of the membrane and soluble proteins 
Membrane-bound FBP was released from IGROVl cells by treat- 
ment with PI-PLC from Bacillus thuringiensis (American Radiola- 
belled Chemicals, St. Louis, MO) as described [3]. The supemate 
forms of FBP produced by KB cell line [8]. In addition, 
cDNA clones obtained from several different carci- 
noma cell lines, including the KB CaCo-2 and IGROVl 
cell lines, share an identical coding region, supporting 
the existence of an interrelationship between the mem- 
brane and soluble forms [3,4,9,10]. We report here the 
purification of both proteins and a comparison of their 
biochemical properties. 
2. MATERIALS AND METHODS 
2.1. Cells 
The human ovarian carcinoma cell line IGROVl was kindly sup- 
plied by Dr. Benard (Institut G. Roussy, Villejuif, France). The cell 
line was grown in roller bottles and maintained in RPMI-1640 con- 
taining a standard concentration of folic acid (2.3 ,uM) supplemented 
with 5% fetal calf serum, 1 mM sodium pyruvate, 2 mM L-glutamine. 
2.2. Antibodies 
The murine MOvl8 (1,k) and MOvl9 (2a,k) monoclonal antibodies 
were used in a purified form [l]. 
2.3. DDIRMA 
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derived from PI-PLC treated cells and the spent medium were inde- 
pendently purified on a MOvl8 immunoaffinity column as described 
[31. 
The purified proteins were loaded onto a non-reducing 12.5% SDS- 
PAGE essentially accordingly to Laemmli [ll], containing 0.025% 
SDS. The gel was then stained using a Silver Stain kit (Bio-Rad) or 
transferred onto nitrocellulose as described [12]. The immunoreaction 
on the transferred protein with MOv18 and MOv19 was performed 
as already described [3]. 
2.5. Degl.vcosylation 
Samples (50 ~1) were incubated for 1 h at 37°C in the presence of 
0.02% SDS, 10 mM EDTA, l%B-mercaptoethanol. 10 mM potassium 
phosphate buffer, pH 7.4, in a final volume of 90~1. p-Octylglucoside 
was added to a final concentration of 0.5%. The incubation with 0.5 
units of endoglycosidase Fm-glycosidase F (Boehringer Mannheim, 
Germany) was performed overnight at 37°C. Control samples were 
incubated in the same conditions but in the absence of the enzyme. All 
samples were analyzed by HPLC as described below. 
2.6. Geljiltratron 
The gel filtration by HPLC was carried out on a TSK G3000 SW 
column (7.5 x 600 mm, Pharmacia LKB, Uppsala, Sweden), equili- 
brated in 100 mM sodium phosphate buffer, pH 7.4. Samples of the 
native and deglycosylated proteins (0.1 ml) were filtered on a 0.45 pm 
HV filter (Millipore S.A. Malsheim, France) and separated at a flow 
rate of 0.5 ml/min. Fractions of 0.5 ml were collected and analyzed by 
DDIRMA for the presence of antigemc activity. The standards used 
for calibration of the column were bovine thyroglobulin (670 kDa). 
bovme gamma globulin (158 kDa), chicken ovalbumin (44 kDa), horse 
myoglobulin (17 kDa) and vitamin B- 12 (1.35 kDa) supplied by Bio- 
Rad. CA. 
2.7. Binding to folk acid 
Each purified protein was incubated in PBS with a 2-fold molar 
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excess of [‘Hlfolic acid (40.4 Ci/mmol, Amersham, UK) at 20°C in a 
dark room for 12-l 5 h. The protein-folic acid complex was separated 
from the free folic acid by gel filtration on Sephadex G-25 equilibrated 
in 50 mM borate buffer, pH 8, 150 mM NaCl and 0.25% gelatine to 
reduce non-specific binding. The radioactivity contained in each of the 
eluted fractions was diluted 1:lO (v/v) with Pica-Fluor 15 (Packard) 
and measured in a Beckman counter type LS 180 1. Alternatively, each 
purified protein was pretreated with cold 0.3 M acetic acid (final 
concentration), pH 3, for 1 h at 4°C. The protein was separated from 
the endogenously bound folic acid by Sephadex G-25 as described 
above. The elution of the folate-free proteins was monitored by 
DDIRMA as described. The protein content of the acid-treated eluted 
samples was assumed to be equivalent to the content of the corre- 
sponding untreated purified proteins eluted from the same column. 
The eluted folate-free samples were assayed for folic acid binding as 
described above. 
3. RESULTS 
The FBPs were isolated from the membrane (mFBP) 
and the spent medium (sFBP) of IGROVl cells by sin- 
gle-step immunoaffinity chromatography on the mono- 
clonal antibody MOv18. Fig. 1A shows the silver stain- 
ing of SDS-PAGE on the purified forms of the FBP. 
The protein purified from the IGROVl conditioned me- 
dium (lane 2) appeared as a single band migrating to an 
apparent A4, of 36 kDa, whereas the purified protein, 
obtained after treatment of the IGROVl membrane 
with PI-PLC (lane l), migrated as a single band corre- 
sponding to 38 kDa. The immunoblotting of the puri- 
fied proteins with MOv18 or MOv19 was consistent 
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Fig. 1. Characterization of the mFBP and sFBP purified from IGROVl. (A) 12.5% SDS-PAGE of the purified FBPs. Samples were silver-stained 
following SDS-PAGE. Lane 1, mFBP; lane 2. sFBP. (B) Immunoblot of the purified FBPs: lanes 1 and 2, mFBP and sFBP Incubated with MOv18, 
lanes 3 and 4, mFBP and sFBP Incubated with MOvl9. 
144 
Volume 317, number 1.2 FEBSLETTERS February 1993 
20 26 30 60 66 60 20 25 30 60 66 60 
Fig. 2. Gel filtration by HPLC of the native and the deglycosylated FBPs purified from IGROVI (A) Purified mFBP before (w;i) and after (M) 
the deglycosylation. (B) Purified sFBP before (w) and after (f&s) the deglycosylation. Arrows indicate where the molecular weight markers eluted. 
with the results obtained by silver staining (Fig. 1B). To 
confirm the results obtained by SDS-PAGE, the puri- 
fied mFBP and sFBP were submitted to gel filtration 
and the elution was monitored by DDIRMA. The 
mFBP was eluted as a single peak corresponding to 40 
kDa and the sFBP also as a single peak corresponding 
to 32 kDa (Fig. 2. An aliquot of the obtained im- 
munoreactive peaks, analyzed in immunoblotting, re- 
sulted to migrate at the same apparent I& of the corre- 
sponding loaded sample (data not shown). The result 
obtained by gel filtration of the sFBP was confirmed in 
several experiments carried out on either the affinity- 
purified or the raw material. To investigate whether the 
difference in M, was due to a different pattern in the 
N-linked carbohydrates, the membrane and the soluble 
forms were treated with N-glycosidase. After enzymatic 
treatment the digested proteins were analyzed by gel 
filtration chromatography. Again two single peaks were 
obtained corresponding respectively to the digested 
mFBP and sFBP. As shown in Fig. 2, the peak corre- 
sponding to mFBP was eluted in a range between 36 and 
29 kDa and the peak of sFBP was eluted in a range 
between 22 and 18 kDa. By the way, the N-glycosidase- 
digested mFBP and sFBP analyzed by SDS-PAGE mi- 
Table I 
Source Protein pmol of folic acid bound to 
olg) the cells* 
Untreated Treated 
1 x lo6 cells treated 0.12 0.2 2.0 
with PI-PLC (mFBP) 
10 ml medium (sFBP) 0.11 0.099 3.2 
*Acid treatment was utilized to released endogenously bound folic 
acid. 
grated as single bands, respectively of about 28 kDa [7] 
and 24 kDa (data not shown). 
To test the capability of mFBP and sFBP to bind folic 
acid, the purified proteins were incubated with [3H]folic 
acid as described in section 2 and the relevant results are 
reported in Table I. Both preparations bound very small 
amounts of folic acid. Assuming that the FBP is univa- 
lent for folate binding, only less than 10% of each pro- 
tein was able to bind to folic acid. Since the MOvl8 and 
MOv19 epitopes are different from the binding site of 
folic acid and analogues, as demonstrated by the bind- 
ing of folic acid to the complexes of mFBP or sFBP with 
MOv18 or MOv19 (data not shown), the presence of 
endogenous folate still bound to the purified proteins 
could not be excluded. In order to investigate if the low 
folate binding capability of the FBPs was due to the 
occupancy of the binding site, an acid treatment was 
performed. The two preparations were treated with ace- 
tic acid and the uncomplexed proteins were separated 
from the free folic acid by gel filtration. After acid treat- 
ment one mol of the purified mFBP and of the sFBP (M, 
of 40 kDa and 32 kDa, according to HPLC), respec- 
tively, bound 0.7 mol and 0.94 mol of folic acid (Table 
I). The lower folate binding capability of the mFBP 
could be attributed to a loss of the folate binding capa- 
bility and/or of the protein amount due to manipula- 
tion. 
4. DISCUSSION 
High-affinity FBP is involved in the assimilation, dis- 
tribution and retention of the vitamin folic acid. Two 
forms of FBP have been described, a membrane-bound 
form and a soluble form found in the culture supernates 
of some tissue culture cell lines. The membrane-bound 
form delivers 5methyltetrahydrofolic acid to the cyto- 
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plasm of folate-depleted cells (reviewed in [13,14] and 
is over-expressed by 90% of ovarian adenocarcinoma 
tumors and tissue culture cell lines. The ovarian carci- 
noma cell line IGROVl is a useful system to investigate 
the relationship between the different forms of FBPs. 
This cell line over-expresses a membrane-associated 
FBP which is solubilized by treatment with PI-PLC, and 
sheds a soluble form into the cell culture medium [2,15]. 
The two purified forms appear to have different sizes 
either as native, denatured or deglycosylated molecules. 
The M, of the mFBP from IGROVl was equivalent o 
that obtained previously by treatment with PI-PLC of 
the mFBP purified from KB ceils [3]. On the other hand, 
the M, of both preparations from IGROVl calculated 
after gel filtration are different from those observed 
analyzing the FBPs from KB [4.5]. In the latter, how- 
ever, the fractionation was performed under different 
condition [ 161. 
Experiments carried out on metabolically labelled 
KB cells, indicates that sFBP originates from mFBP 
removed from the cell membrane [8]. This is in keeping 
with our finding that the mFBP and sFBP have proper- 
ties indicating that they share at least three sites of 
protein sequence. In fact, they are both able to bind folic 
acid to the same degree. In addition, both proteins are 
recognized by two monoclonal antibodies, MOv18 and 
MOv19 [2,15], which bind to two different epitopes. 
thus indicating that they share two antigenic determi- 
nants. This fact, in addition to the lack of the cross- 
reactive determinant on the soluble protein [15] might 
suggest hat the shedding of the protein could be due to 
cleavage by a protease. In vitro studies on erythrocytes 
FBP demonstrated that the hydrophobic form of FBP 
is converted to the hydrophilic form by trypsin [17]. 
Moreover, a Mg2+-dependent protease from human pla- 
centa [18] and a metalloprotease from KB cell [19] have 
been identified which can generate the hydrophilic form 
of FBP. It is also possible that the sFBP is first released 
by the action of an endogenous phospholipase and then 
cleaved by a protease. Finally, the membrane and solu- 
ble forms of FBP could be encoded by different mem- 
bers of the same gene family or that they arise through 
alternative splicing of transcripts from the same gene as 
is a possible explanation for the origin of the polypep- 
tide-anchored and phosphatidyl-inositol-anchored forms 
of the human immunoglobulin G receptor CD 16 [20]. 
A model has been suggested in which the folate recep- 
tor recycles while remaining tightly associated to the cell 
membrane [21]. However, it is still unclear why the re- 
ceptor is shed from the cell membrane. The ovarian 
carcinoma seems to be a good model for studies con- 
cerning the folate metabolism and the biological impor- 
tance of FBPs in tumor cells. 
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